Immutep Crecimiento futuro

Future controles de criterios 5/6

Immutep se prevé un crecimiento anual de los beneficios y los ingresos de 57% y 47.6% respectivamente. Se prevé que el BPA sea de grow en 52.4% al año. Se prevé que la rentabilidad de los fondos propios sea de -187.7% en 3 años.

Información clave

60.3%

Tasa de crecimiento de los beneficios

69.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.7%
Tasa de crecimiento de los ingresos	71.2%
Rentabilidad financiera futura	-68.8%
Cobertura de analistas	Good
Última actualización	04 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:YP1A - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	163	47	98	58	4
6/30/2025	17	-43	-63	-42	4
6/30/2024	3	-46	-47	-46	5
12/31/2023	4	-41	-42	-42	N/A
9/30/2023	4	-40	-39	-39	N/A
6/30/2023	4	-40	-35	-35	N/A
3/31/2023	4	-38	-33	-33	N/A
12/31/2022	4	-37	-30	-30	N/A
9/30/2022	5	-34	-30	-30	N/A
6/30/2022	5	-32	-30	-30	N/A
3/31/2022	4	-29	-25	-25	N/A
12/31/2021	4	-26	-20	-20	N/A
9/30/2021	4	-28	-19	-19	N/A
6/30/2021	4	-30	-18	-18	N/A
3/31/2021	5	-29	-16	-16	N/A
12/31/2020	6	-27	-15	-15	N/A
9/30/2020	10	-20	-13	-13	N/A
6/30/2020	14	-13	-11	-11	N/A
3/31/2020	13	-15	-13	-13	N/A
12/31/2019	13	-16	-14	-14	N/A
9/30/2019	9	-17	-15	-15	N/A
6/30/2019	6	-18	-15	-15	N/A
3/31/2019	5	-18	-13	-13	N/A
12/31/2018	5	-17	-10	-10	N/A
9/30/2018	6	-15	-9	-9	N/A
6/30/2018	7	-13	-8	-8	N/A
3/31/2018	6	-12	-8	-8	N/A
12/31/2017	7	-10	-8	-8	N/A
9/30/2017	5	-9	N/A	-8	N/A
6/30/2017	4	-9	N/A	-9	N/A
3/31/2017	3	-10	N/A	-8	N/A
12/31/2016	2	-10	N/A	-9	N/A
9/30/2016	2	-36	N/A	-10	N/A
6/30/2016	2	-62	N/A	-11	N/A
3/31/2016	2	-71	N/A	-10	N/A
12/31/2015	1	-82	N/A	-8	N/A
9/30/2015	1	-57	N/A	-8	N/A
6/30/2015	1	-32	N/A	-8	N/A
3/31/2015	1	-23	N/A	-10	N/A
12/31/2014	1	-14	N/A	-13	N/A
9/30/2014	2	-14	N/A	-13	N/A
6/30/2014	2	-13	N/A	-14	N/A
3/31/2014	2	-13	N/A	-14	N/A
12/31/2013	2	-13	N/A	-14	N/A
9/30/2013	2	-14	N/A	-15	N/A
6/30/2013	2	-15	N/A	-16	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: YP1A se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.6%).

Beneficios vs. Mercado: YP1A se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: YP1A se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: YP1ASe prevé que los ingresos de la empresa (47.6% al año) crezcan más deprisa que los del mercado German (4.6% al año).

Ingresos de alto crecimiento: YP1ASe prevé que los ingresos de la empresa (47.6% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: YP1A se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Immutep Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates

Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC

Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha

Immutep Limited Reveals a New anti-LAG-3 Research Program

Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021

Immutep Limited Reports Positive Final Data from Insight-004 Trial

Immutep Limited Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

Immutep Limited Provides an Update on its Clinical and Preclinical Programs

Immutep Limited Enters Second Collaboration with Merck & Co., Inc. for New Randomised Phase IIB Trial in Head and Neck Cancer

Immutep Limited Expands Part B of TACTI-002 Collaboration Trial

Immutep Limited Announces Advancement of Phase II Trial for Eftilagimod Alpha in COVID-19 Patients to Randomised Portion of the Study

Immutep Limited Completes Safety Run-In Data Review of the First Six Patients from the Phase Ii Clinical Trial of Eftilagimod Alpha Treatment by Immune Modulation in COVID-19 Disease

Immutep Limited Discontinues its Phase II Clinical Trial Evaluating an Anti-Lag3 Cell Depleting Monoclonal Antibody, GSK2831781

Immutep Limited Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

Immutep Limited Announces Executive Changes

Immutep Limited Plans to Increase the Efti Manufacturing Process

Immutep Limited Announces Operational Update

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

Immutep Limited announced that it expects to receive AUD 29.572005 million in funding

Immutep Limited Announces Expansion of TACTI-002 Collaboration Trial

Immutep Limited Announces New Interim Data from Its Ongoing Phase II Tacti-002 Study

Immutep Limited to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

Immutep Limited Announces Improving Results from Stage I of Phase II TACTI-002 Study

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento